FDA sent a peptide "interim access policy" to the White House. Its text is not public.

What the official record shows

The Office of Information and Regulatory Affairs (OIRA), part of the White House Office of Management and Budget, publishes a list of regulatory actions it is reviewing.[1][2] In the version run on October 15, 2026, one FDA entry reads: RIN 0910-ZD94, "Interim Access Policy for Compounding Using Certain Peptides," stage "Notice," received October 14, 2026, economically significant "No," legal deadline "None."[1] That is the whole entry. It has no text, no list of substances and no conditions.

Reuters and the Associated Press reported the filing on Thursday, October 15; OIRA's list gives the receipt date as October 14.[1][2][3] Reuters said the filing gave no further details.[2] pepmg searched the Federal Register on October 16, 2026 for FDA documents mentioning peptides published since September 1, 2026, and found none.[14]

What is reported, not documented

Unnamed sources, one named peptide

The AP reported, citing two people familiar with the plan, that the policy would let pharmacies temporarily compound some popular peptides, naming BPC-157, and that it would reportedly assure compounding pharmacies they will not be targeted, an approach known as enforcement discretion.[3] HHS officials did not respond to the AP's requests for comment.[3] The AP added that formally adding peptides to FDA's compounding list would require rulemaking that could take years, and that it is unclear whether the administration will pursue it.[3]

Pink Sheet's summary describes the item as a temporary order that would allow compounding and dispensing of certain unapproved injectable peptide products, and frames it as a debate between career FDA staff and HHS leadership.[5] Earlier in October, the Washington Post reported, again from two unnamed people, that the administration was drafting plans to allow temporary sale of some previously restricted peptides while officials write new regulations, that it was unclear which peptides would be included, and that officials were seeking guardrails.[6] The Post quoted Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, a trade group, proposing conditions such as enhanced patient disclosures, serious adverse event reporting and data collection on peptide use.[6] Those are a trade group's proposals, not terms in any published FDA document.

How it got here

FDA's staff said no to all seven. The panel said yes to six.

On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee considered seven peptides for the 503A bulks list, the list of bulk substances that state-licensed pharmacists and physicians may compound with when a substance has no USP monograph and is not part of an approved drug.[7][8][12] FDA's briefing document proposed that none of the 14 substances reviewed, the free base and acetate forms of each peptide, be included.[8] The same document records that every nomination for the seven had been withdrawn by its nominator, and that FDA elected to present them to the committee anyway.[8]

The committee narrowly recommended six: BPC-157 , KPV , TB-500 , MOTS-c , Semax and Epitalon . It did not recommend emideltide, also sold as DSIP .[4][9] Advisory votes are advice to FDA; our July note covers the vote and FDA's evidence reviews in detail.

FDA's own safety-risk page still carries its concerns about these substances. For KPV, MOTS-c and TB-500, FDA writes that it has not identified any human exposure data; for BPC-157 and Semax, it has "no, or only limited" or "no, or limited" safety-related information for the proposed routes.[11]

Status, checked Oct. 16, 2026

Where the seven sit on FDA's lists today

FDA's interim policy sorts nominated substances into categories. For category 1, FDA says it "does not intend to take action against a compounder" if the guidance's conditions are met; for category 2, substances with significant safety risks, FDA "would consider taking action."[12] FDA's page also says it does not intend to place substances nominated on or after January 7, 2025 into these categories.[12]

In FDA's nominations document, updated May 14, 2026 and read on October 16, none of the seven July peptides appears in category 1.[10] FDA's safety-risk page, dated April 2026, lists all seven under "bulk drug substances nominated but withdrawn," described as substances "previously in category 2" whose nominations "were withdrawn by the nominators"; that section held 16 entries when read on October 16.[11] Category 2 of the same nominations document still names ibutamoren mesylate and kisspeptin-10, a form of Kisspeptin .[10]

The existing category 1 policy therefore does not name any of the July peptides. Whether the new document adds a peptide-specific route, and for which substances, is exactly what its unpublished text would settle.

Three things this note is not saying

It is not saying the policy has been issued. As of the OIRA list run on October 15, it was under review, and pepmg found no published text.[1][14]

It is not saying any peptide is approved, or that a final rule has changed the 503A bulks list. FDA says it builds that list through notice-and-comment rulemaking, and it announced the July meeting in the Federal Register as a request for advice and comment.[12][13]

It is not saying anything about research-labeled vials sold online. The reported policy concerns pharmacy compounding.[3][5] This note reports regulatory status, not medical or legal advice.

Questions people are asking